Citing increasing demand from doctors to assess diseases close up, the Australian investment news service Stockhead has included Imagion Biosystems (ASX:IBX) among “Ten ASX medical imaging stocks that make a pretty picture.”
The article notes that several of the stocks mentioned could benefit from a trend in cancer medicine toward more thorough investigation of suspicious tissues prior to surgical biopsy. In animal studies using antibody-conjugated nanoparticles to recognize signs of malignant cancer, Imagion Biosystems’ MagSense technology enables direct molecular interrogation of suspicious tissues, where a primary tumor may be present, without surgical biopsy.
Visit Stockhead to read Ten ASX medical company stocks that make a pretty picture.
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited